Murray Laugesen is a prominent physician and campaigner for safer tobacco alternatives in New Zealand. He was one of the first people to get interested clinically in the potential of e-cigarettes, and has conducted a number of studies over the last couple of years.
The latest has just been published in the journal tobacco Control, and makes for some very encouraging reading.
Happily, the paper is fully accessible from here: Untitled Document
From the study's conclusion:
The latest has just been published in the journal tobacco Control, and makes for some very encouraging reading.
Happily, the paper is fully accessible from here: Untitled Document
From the study's conclusion:
The Ruyan V8 16 mg ENDD reduced desire to smoke more than
the placebo ENDD and during 9 h of use was well tolerated,
acceptable to most users, rated significantly more pleasant to use
than the inhalator, and in the first hour exhibited a pharmacokinetic
profile more like the inhalator than a tobacco cigarette,
without excess adverse events. These findings suggest potential
to help people stop smoking in the same way as a nicotine
inhalator. Our findings should be regarded as preliminary and
need to be confirmed for this and other brands of ENDD. The
nicotine pharmacokinetics of ENDDs should be confirmed in
other studies, and different ways of using these devices need to
be explored. A large, well-conducted randomised trial is needed
to evaluate the ENDD’s efficacy as a quitting aid and to identify
any delayed or long-term adverse effects.
Last edited: